Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 7/20 | 0.44 |
| ▸ | PRKCA | P17252 | 3/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.38 |
| ▸ | PRKCG | P05129 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | PRKCH | P24723 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27249375 | 1.00 | MAPT (0.44) | MAPTMAPK1TLR2PRKCAPRKCE | |
| SCHEMBL27249374 | 1.00 | MAPT (0.44) | MAPTMAPK1TLR2PRKCAPRKCE | |
| SCHEMBL30837956 | 1.00 | MAPT (0.44) | MAPTMAPK1TLR2PRKCAPRKCE | |
| SCHEMBL27303897 | 1.00 | MAPT (0.44) | MAPTMAPK1TLR2PRKCAPRKCE | |
| SCHEMBL27303866 | 1.00 | MAPT (0.44) | MAPTMAPK1TLR2PRKCAPRKCE | |
| SCHEMBL30837983 | 1.00 | MAPT (0.44) | MAPTMAPK1TLR2PRKCAPRKCE | |
| SCHEMBL27249373 | 1.00 | MAPT (0.44) | MAPTMAPK1TLR2PRKCAPRKCE | |
| SCHEMBL27255570 | 0.97 | MAPT (0.45) | MAPTMAPK1TLR2PRKCAPRKCE | |
| SCHEMBL27299400 | 0.95 | TLR2 (0.41) | MAPTMAPK1TLR2PRKCAPRKCE | |
| SCHEMBL27299402 | 0.95 | TLR2 (0.41) | MAPTMAPK1TLR2PRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102347-A1 | Sulfur-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | NANOVATION THERAPEUTICS INC. (CA) | 2026-04-16 | — | — | US | disclosed |
| EP-4594298-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS | Nanovation Therapeutics Inc. (CA) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024065042-A1 | SULFUR-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102347-A1 | Sulfur-Containing Ionizable Lipids for the Delivery of Therapeutic Agents | NSUN2, SGMS2, SGMS1 | MAPT 4163/4885MAPK1 3488/4885TLR2 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.